ArticleMolecular pharmaceutics2018
PEG-Peptide Inhibition of Scavenger Receptor Uptake of Nanoparticles by the Liver.
Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.Nature communications · 2024Pooled it
- Effects of Oligolysine-Polyethylene Glycol Coating on the Biodistribution of Wireframe DNA Origami Nanosheets in Zebrafish Embryos.ACS nano · 2025Article
- Review
- Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery.Current opinion in biotechnology · 2024Review
- Macrophage-Targeting DNA Nanomaterials: A Future Direction of Biological Therapy.International journal of nanomedicine · 2024Review
- Principles of Nanoparticle Delivery to Solid Tumors.BME frontiers · 2023Review
- Nonviral delivery systems for antisense oligonucleotide therapeutics.Biomaterials research · 2022Review
- Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer.Seminars in liver disease · 2022Review
- DNA flowerstructure co-localizes with human pathogens in infected macrophages.Nucleic acids research · 2020Article
- Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines.Science advances · 2020Article
- Heat-shrinking DNA nanoparticles for in vivo gene delivery.Gene therapy · 2020Article
- Functionalization of Liposomes with Hydrophilic Polymers Results in Macrophage Uptake Independent of the Protein Corona.Biomacromolecules · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PEGylated polylysine peptides represent a new class of scavenger receptor inhibitors that may find utility at inhibiting DNA nanoparticle uptake by Kupffer cells in the liver. PEG-peptides inhibit scavenger receptors in the liver by a novel mechanism involving in situ formation of albumin nanoparticles. The present study developed a new in vivo assay used to explore the structure-activity-relationships of PEG-peptides to find potent scavenger receptor inhibitors. Radio-iodinated PEG-peptides were dosed i.v. in mice and shown to saturate liver uptake in a dose-dependent fashion. The inhibition potency (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.